Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurogene (NGNE)
NASDAQ:NGNE
Holding NGNE?
Track your performance easily
NGNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.49 - $74.49
Previous Close$34.52
Volume454.98K
Average Volume (3M)186.93K
Market Cap
$448.47M
Enterprise Value$308.35M
Total Cash (Recent Filing)$153.91M
Total Debt (Recent Filing)$13.79M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 09, 2024EPS Estimate
-$1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.71
Shares Outstanding12,993,613
10 Day Avg. Volume608,434
30 Day Avg. Volume186,931
Standard Deviation0.29
R-Squared0.07
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.89
Price to Sales (P/S)550.65
Price to Cash Flow (P/CF)-8.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue333.36
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.02
Forecast
1Y Price Target
$63.80Price Target Upside84.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Neurogene News
PremiumCompany Announcements
Neurogene Reports Promising Interim Results for NGN-401 Trial
PremiumCompany Announcements
Neurogene Secures $200M for Genetic Therapy DevelopmentBulls Say, Bears Say
Bulls Say
Clinical Execution And SafetyManagement's clinical execution and regulatory engagement contribute positively, with early Phase 1/2 validation of safety showing no signs of toxic overexpression.
Competitive AdvantageImprovements on RSBQ with NGN-401 appear better and more consistent compared to competitor TSHA-102.
Efficacy And ApprovalNeurogene announced initial interim clinical data for NGN-401 in Rett syndrome, and the efficacy data is believed to be good enough to support approval.
Bears Say
Clinical TrialsAn emerging treatment-related SAE was identified in the third high-dose participant, raising concerns despite prophylactic immunosuppression.
Regulatory ChallengesNGNE terminated the CLN5 Batten disease program following FDA denial of RMAT designation.
Treatment SafetyHigh-dose NGN-401 led to one AAV-related SAE and Grade 2/3 liver enzyme elevations.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $12.49 and its highest was $74.49 in the past 12 months.
What is Neurogene’s market cap?
Currently, no data Available
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is Aug 09, 2024 which is 101 days ago.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on May 10, 2024. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.034 by $0.034.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -$1.05.
How many shares outstanding does Neurogene have?
Neurogene has 12,993,613 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$1 in its last earnings report, beating expectations of -$1.034. Following the earnings report the stock price went down -2.627%.
Which hedge fund is a major shareholder of Neurogene?
Among the largest hedge funds holding Neurogene’s share is Baker Bros Advisors LP. It holds Neurogene’s shares valued at 19M.
---
Neurogene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.80 (84.85% Upside)
$63.80 (84.85% Upside)
Blogger Sentiment
Bullish
NGNE Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 18.9%
Last 30 Days ▲ 38.6%
Last 30 Days ▲ 38.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
150.10%
12-Months-Change
Fundamentals
Return on Equity
-47.27%
Trailing 12-Months
Asset Growth
91.29%
Trailing 12-Months
Company Description
Neurogene
Neoleukin Therapeutics, Inc. is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
---
NGNE Stock 12 Month Forecast
Average Price Target
$63.80
▲(84.85% Upside)
Technical Analysis
Best Analysts Covering NGNE
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+25.04%
reiterated a buy rating 6 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +25.04% per trade.
---